ADC Therapeutics SA logo

ADC Therapeutics SA(ADCT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
SELL
SELL for 3 days
PROFIT SINCE LAST BUY
-21.38% ▼
LAST CLOSE
$1.37
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ADCT

11/18/2026: ADCT (2-star) is a SELL. SELL for 3 days. Simulated Profits (-21.38%). Updated daily EoD!

ADC Therapeutics SA is a commercial-stage biotechnology company that discovers and develops antibody-drug conjugates to treat hematological cancers and solid tumors. Its primary commercial product, Zynlonta, provides established revenue and validates its proprietary PBD technology platform, though the company continues to operate at a net loss while funding clinical trials. Key growth opportunities center on expanding Zynlonta into earlier treatment lines and advancing pipeline candidates, counterbalanced by intense oncology competition and ongoing capital needs. The stock is best suited for growth-oriented investors comfortable with high clinical and market volatility. Key developments to monitor include quarterly Zynlonta sales figures and clinical pipeline readouts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers potential top-line revenue expansion from Zynlonta and pipeline maturation, balanced by early-stage execution risks.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp price movements surrounding clinical updates and quarterly sales results.
Value investorWeak fitThe company currently operates at a net loss, making traditional valuation metrics challenging to apply favorably.
Dividend investorWeak fitADC Therapeutics does not pay dividends and retains all capital for corporate growth and R&D.
Low-risk investorWeak fitHigh clinical, regulatory, and market volatility inherent to small-cap biotechnology firms present significant risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotechnology stocks frequently experience rapid price swings based on clinical readouts and commercial updates.
Valuation riskMedium / highValuation depends heavily on future clinical success and sales projections rather than current net profitability.
Competition risk (CD19 therapies and oncology markets)HighIntense competition from established therapies and alternative modalities can restrict market share expansion.
Business qualityMediumPossesses a validated proprietary technology platform and an FDA-approved product, but scale is still developing.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess relies heavily on commercial execution for Zynlonta and effective clinical trial execution for pipeline assets.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 189.89M USD
Price to earnings Ratio -
1Y Target Price 3.33
Price to earnings Ratio -
1Y Target Price 3.33
Volume (30-day avg) 1.6M shares
Beta 1.8
52 Weeks Range 0.78 - 4.98
Updated Date 11/18/2026
52 Weeks Range 0.78 - 4.98
Updated Date 11/18/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.5

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.0%
Active BUY / eligible
67 / 108
30-Day BUY Count Change
+22
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
91.7%
Active BUY / eligible
11 / 12
30-Day BUY Count Change
+6

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 222.79%
Avg. Invested days 28
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ADCT receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ADCT has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, moderate earnings growth (+9.6%) and solid revenue growth (+14.9%) are partially offset by weak cash generation (FCF margin -173.8%), weak profitability (net margin -175.3%).

Financial Health Rating

★★★★★
ADCT's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 73.1%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is ADCT's strongest growth driver at +14.9% FY2025 versus FY2024 (solid, 4 stars). By comparison, while free-cash-flow growth (-13.4%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 66.9% and approximately 89.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 13.09% supports management-shareholder alignment.

Top 5 Institutional Investors

Nantahala Capital Management, LLC 19.30%
Redmile Group, LLC 9.02%
TCG Crossover Management, LLC 8.92%
Prosight Management, LP 6.13%
BlackRock Inc 5.50%

Unit Economics (Per $1K Revenue)

★★★★★
ADCT generates approximately $906 of gross profit, $-1,332 of operating income, and $-1,738 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.11%

Quantitative Style Profile

★★★★★
ADCT has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product Sales (Zynlonta)Net commercial sales of Zynlonta to hospitals, clinics, and specialty distributors primarily in the United States.The primary financial engine of the company, driven by prescriptions and adoption of its lead drug.
License and Collaboration FeesUpfront payments, milestone fees, and royalties from collaborative partnerships utilizing ADC Therapeutics' technology.Provides secondary, non-dilutive capital streams through partnerships with other drug developers.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 102.73M
Price to Sales(TTM) 2.24
Enterprise Value 102.73M
Price to Sales(TTM) 2.24
Enterprise Value to Revenue 1.21
Enterprise Value to EBITDA -1.43
Shares Outstanding 140.66M
Shares Floating 125.27M
Shares Outstanding 140.66M
Shares Floating 125.27M
Percent Insiders 13.09
Percent Institutions 66.88

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.